Impact News +++ Rolls-Royce stock is quietly turning into an AI play (Fool) +++ ROLLS ROYCE Aktie -3,28%

CROSSJECT Aktie

>CROSSJECT Aktienkurs

1.96 EUR -0.3% (Tradegate)

Ask: 1.994 EUR / 560 Stück

Bid: 1.958 EUR / 570 Stück

Tagesumsatz: 570 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

CROSSJECT Aktie über LYNX handeln

Intraday

1 Jahr

>CROSSJECT Performance

1 Woche: -0,5%

1 Monat: -6,6%

3 Monate: -19,7%

6 Monate: +17,4%

1 Jahr: +4,6%

laufendes Jahr: -6,6%

>CROSSJECT Aktie

Name:

CROSSJECT SA EO -,10

Land:

Frankreich

Sektor:

Gesundheit

ISIN/ Wkn:

FR0011716265 / A1XEH4

Symbol/ Ticker:

74C (Frankfurt)

Kürzel:

FRA:74C, ETR:74C, 74C:GR

Index:

Webseite:

https://www.crossject.com..

Profil:

Crossject S.A. is a pharmaceutical company special..
>Volltext..

Marktkapitalisierung:

99.4 Mio. EUR

Unternehmenswert:

110.85 Mio. EUR

Umsatz:

EBITDA:

-7.85 Mio. EUR

Nettogewinn:

-11.19 Mio. EUR

Gewinn je Aktie:

-0.23 EUR

Schulden:

17.57 Mio. EUR

Liquide Mittel:

6.3 Mio. EUR

Operativer Cashflow:

Bargeldquote:

1.09

Umsatzwachstum:

-100%

Gewinnwachstum:

-7.48%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CROSSJECT

Letzte Datenerhebung:

02.02.26

>CROSSJECT Kennzahlen

Aktien/ Unternehmen:

Aktien: 52.13 Mio. St.

Frei handelbar: 64.87%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: 108

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 158.48%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -34.92%

Eigenkaprendite: -

>CROSSJECT Peer Group

Gesundheit

>CROSSJECT Chart & Kurs - Tradegate

>CROSSJECT News

02.02.26 - 07:18	CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group) (GlobeNewswire EN)
	CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)...

14.11.25 - 20:48	CROSSJECT completes €5 million financing with Vatel Capital (GlobeNewswire EN)
	Press release...

24.09.25 - 22:03	CROSSJECT presents its financial results and key highlights for the first half of 2025 (GlobeNewswire EN)
	Press release...

22.09.25 - 07:33	CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam) (GlobeNewswire EN)
	Press release...

04.08.25 - 17:39	CROSSJECT remains engaged during the summer break (GlobeNewswire EN)
	Press Release...

24.06.25 - 19:03	CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause (GlobeNewswire EN)
	Press release...

11.06.25 - 07:33	CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children (GlobeNewswire EN)
	Press release...

03.06.25 - 07:33	Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00 (GlobeNewswire EN)
	Press release...

27.05.25 - 07:33	CROSSJECT implements new manufacturing module to scale-up the ZENEO® Factory ′s versatility and capacity in anticipation of full product pipeline deployment (GlobeNewswire EN)
	Press release...

20.05.25 - 07:33	CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval (GlobeNewswire EN)
	Press Release...

15.05.25 - 07:33	CROSSJECT′s ZENEO® needle-free autoinjector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors (GlobeNewswire EN)
	Press Release...

07.05.25 - 07:33	CROSSJECT provides updates on the EUA filing of ZEPIZURE® (GlobeNewswire EN)
	Press Release...

27.03.25 - 07:33	CROSSJECT reports financial results for 2024 (GlobeNewswire EN)
	Press Release...

25.03.25 - 07:33	CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program (GlobeNewswire EN)
	Press Release...

18.03.25 - 17:39	CROSSJECT achieves key ZEPIZURE® manufacturing batch stability milestones (GlobeNewswire EN)
	Um den gesamten Artikel unter globenewswire.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.25 - 07:33

Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board (GlobeNewswire EN)

Dijon, FRANCE, February 12, 2025 – 0730 (CET) – Crossject (ISIN: FR0011716265; Euronext Growth : ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergency situations, today announces that, as of February 17, its Executive Board will be made up of Patrick Alexandre, Chairman, and Isabelle Liebschutz, Quality and Regulatory Affairs Director and the Company's qualified person. Their terms of office were renewed by the Supervisory Board at its meeting on 11 February, for a period of 4 years. Olivier Giré's membership of the Executive Board was not renewed in view of his upcoming departure from Crossject, and will expire on February 17, 2025....

06.02.25 - 07:33

COMPLETION OF THE TRANSACTIONS ANNOUNCED IN DECEMBER 2024 RELATING TO THE AMENDMENT OF THE CONVERTIBLE BONDS SUBSCRIBED BY AN ENTITY AFFILIATED TO HEIGHTS CAPITAL MANAGEMENT, INC. (“HEIGHTS”) AND THE ISSUE OF A SECOND ASSIMILABLE TRANCHE (GlobeNewswire EN)

Press ReleaseDijon, FRANCE, February 6, 2025 –0730h (CET) – Crossject (ISIN: FR0011716265; Euronext Growth : ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergency situations, today announces, in accordance with the agreement entered into with Heights in December 2024, the completion of the amendments of the terms and conditions of the bonds issued to an entity affiliated to Heights (the "Investor") in February 2024, and the issue to the Investor of a second tranche of a nominal value of €2,496,400 at an issue price representing 90% of the nominal value of the bonds, ie. €2,246,400 (the “Transaction”)....

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Es gibt ja nur zwei Sorten Menschen, die einen kultivierten Mann faszinieren können: Menschen, die alles wissen, und Menschen, die überhaupt nichts wissen. - Oscar Wilde

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram